Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RBM (Rules-Based Medicine) bags German cell culture test company:

This article was originally published in Clinica

Executive Summary

Biomarker testing services provider Rules-Based Medicine (RBM) has bought human cell culture test systems firm Experimentelle and Diagnostische Immunologie (EDI) for an undisclosed fee. The two companies will collaborate to combine their technologies and develop biomarker test platforms - EDI's human organotypic (HOT) cell culture test systems complements RBM's Multi-Analyte Profiling (MAP) biomarkers for proteins, metabolites and other substances in the human blood. According to Austin, Texas-based RBM, the collaboration will help to standardise sample collection, cell treatment and result generation, and will make therapeutic and consumer product development more reliable and reproducible. EDI will become a subsidiary of RBM but will retain its operating facilities in Reutlingen, Germany.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049941

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel